The effect of rapid lipid lowering with atorvastatin on autonomic parameters in patients with coronary artery disease.

[1]  A. Malliani,et al.  Sympathetic overactivity in ischaemic heart disease. , 2004, Clinical science.

[2]  C. Antzelevitch,et al.  Autonomic aspects of arrhythmogenesis: the enduring and the new , 2004, Current opinion in cardiology.

[3]  I. Zucker,et al.  Simvastatin Normalizes Autonomic Neural Control in Experimental Heart Failure , 2003, Circulation.

[4]  J. Balligand,et al.  Rosuvastatin Decreases Caveolin-1 and Improves Nitric Oxide–Dependent Heart Rate and Blood Pressure Variability in Apolipoprotein E−/− Mice In Vivo , 2003, Circulation.

[5]  A. Struthers,et al.  Intensive statin treatment improves baroreflex sensitivity: another cardioprotective mechanism for statins? , 2002, Heart.

[6]  H. Krum,et al.  Altered sympathetic and parasympathetic activity in lung transplantation patients at rest and following autonomic perturbation. , 2002, Chest.

[7]  Y. Hirooka,et al.  Role of Nitric Oxide in Central Sympathetic Outflow , 2001, Experimental biology and medicine.

[8]  V. Athyros,et al.  Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. , 2001, Atherosclerosis.

[9]  P. Puddu,et al.  HMG-CoA Reductase Inhibitors: Is the Endothelium the Main Target? , 2001, Cardiology.

[10]  W. Sessa,et al.  Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. , 2000, American journal of physiology. Heart and circulatory physiology.

[11]  G. Thorgeirsson,et al.  Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. , 2000, The American journal of cardiology.

[12]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[13]  J. Navarro-Antolín,et al.  Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. , 1998, The Journal of clinical investigation.

[14]  J Haaksma,et al.  Depressed heart rate variability is associated with events in patients with stable coronary artery disease and preserved left ventricular function. REGRESS Study Group. , 1998, American heart journal.

[15]  Gert B. M. Mensink,et al.  The relationship between resting heart rate and all-cause, cardiovascular and cancer mortality. , 1997, European heart journal.

[16]  A. Tonkin,et al.  Poincaré plot of heart rate variability allows quantitative display of parasympathetic nervous activity in humans. , 1996, Clinical science.

[17]  C. Funck-Brentano.  Are intracardiac electrophysiological studies in healthy volunteers ethical? Time for multinational recommendations. , 1995, Journal of Cardiovascular Pharmacology.

[18]  J. Floras.  Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. , 1993, Journal of the American College of Cardiology.

[19]  J. Fleiss,et al.  Frequency Domain Measures of Heart Period Variability and Mortality After Myocardial Infarction , 1992, Circulation.

[20]  J Ross,et al.  Influence of heart rate on mortality after acute myocardial infarction. , 1990, The American journal of cardiology.

[21]  R S Paffenbarger,et al.  Heart rate and cardiovascular mortality: the Framingham Study. , 1987, American heart journal.

[22]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[23]  James B. Martins.  Sympathetic influences in myocardial ischemia: possible mechanisms of arrhythmogenesis. , 1983, Cardiology clinics.

[24]  J. Feldman,et al.  Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. , 1991, American heart journal.